Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification

Publisher： Karger

E-ISSN： 1662-6575|8|1|83-87

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.8, Iss.1, 2015-02, pp. : 83-87

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sorafenib Induces Therapeutic Response in a Patient with Metastatic Collecting Duct Carcinoma of Kidney

By  

Oncology Research and Treatment, Vol. 32, Iss. 1-2, 2009-01 ,pp. : 44-46

Karger

Access to resources Recommend Favorite

Mutational analysis and clinical correlation of metastatic colorectal cancer

By  

CANCER, Vol. 120, Iss. 10, 2014-05 ,pp. : 1482-1490

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 185-191

Karger

Access to resources Recommend Favorite

Flt3L Therapy following Localized Tumor Irradiation Generates Long-Term Protective Immune Response in Metastatic Lung Cancer: Its Implication in Designing a Vaccination Strategy

By  

Oncology, Vol. 70, Iss. 4, 2006-10 ,pp. : 245-254

Karger

Access to resources Recommend Favorite

Improving Patient Outcomes with Regorafenib for Metastatic Colorectal Cancer - Patient Selection, Dosing, Patient Education, Prophylaxis, and Management of Adverse Events

By  

Oncology Research and Treatment, Vol. 38, Iss. 6, 2015-05 ,pp. : 300-308

Karger

Access to resources Recommend Favorite